|drug1480||FAVICOVIR 200 mg Film Tablet Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Description: Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hoursMeasure: AUC0-tlast of Favipiravir Time: 0 to 24 hours post-dose
Description: Maximum plasma concentration of favipiravirMeasure: Cmax of Favipiravir Time: 0 to 24 hours post-dose
Description: Area under the plasma concentration curve to infinite time of favipiravirMeasure: AUC0-inf of Favipiravir Time: 0 to 24 hours post-dose
Description: Time to reach maximum plasma concentration of favipiravirMeasure: Tmax of Favipiravir Time: 0 to 24 hours post-dose
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports